Why we test before we buy, and why we sometimes pass on the most-hyped platforms.
When a new aesthetic technology launches, manufacturers approach clinics aggressively. Demos, training, financing options. Many clinics buy quickly to be first to market with the new platform. We have learned to be slow.
Our process. We track new platforms through the FDA approval timeline and the early peer-reviewed clinical literature. We follow what experienced practitioners abroad are saying after the launch hype settles. We attend trade events to see the platforms in person and ask hard questions of the engineers. We talk to clinics that have had the equipment for six to twelve months and ask what their honest experience has been.
Only after this does the platform come up for serious consideration. Even then, we run a clinical trial of our own, treating a small group of clients (with their full informed consent) on a test basis, photographing and measuring outcomes, comparing the result to what we can achieve with our existing equipment. If the new platform delivers materially better outcomes for a real population of clients, we proceed.
Why this slowness. Many launched platforms quietly disappoint. The early marketing claims do not hold up to longer clinical use. The platforms that survive five years are the ones with real evidence, the rest are forgotten. By being slow, we miss the early novelty period but we acquire what actually works.
What we have passed on. Quite a few. Without naming specific platforms, we have declined plasma devices, certain bioactive injectables, several light-based platforms, and a number of "next generation" treatments that did not pass our internal trial. Some of these are now standard in other clinics. We are not embarrassed about declining them.
What we have invested in. Established RF platforms (Thermage, Exion, Viora, Venus Viva). Trusted laser families (Soprano, Candela, Alma). Bio-remodelling injectables from manufacturers with strong clinical evidence. Body sculpting platforms with substantial peer-reviewed support. We tend to choose proven over novel.
The result is a treatment menu that is less novel than some clinics offer but more reliable session by session. The same approach extends to product brands, training partners, and continuing education. Our clients receive what works, not what is currently in fashion.
We will continue to evaluate new platforms as they emerge. We will continue to be slow. That is the standard we built the clinic on.